M. Lassen
Internal Medicine · 2001–2010
A researcher in the Science corpus: 13 papers; trusts 2 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Internal Medicine — 63 citations into it; #19 of 19 by trust here, #2 by citations
- Cardiology and Cardiovascular Medicine — 52 citations into it
Whom M. Lassen trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts M. Lassen overall
Papers from M. Lassen's perspective
Ordered by how strongly the researchers M. Lassen trusts endorse each paper. Same corpus, a different order for every researcher.
- Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. (New England Journal of Medicine)
- GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. (Journal of Clinical Epidemiology)
- Oral apixaban for the treatment of acute venous thromboembolism. (New England Journal of Medicine)
- Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (New England Journal of Medicine)
- Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. (Chest)
- Nonparametric Estimation from Incomplete Observations
- Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. (Archives of Internal Medicine)
- Dabigatran versus warfarin in the treatment of acute venous thromboembolism. (New England Journal of Medicine)
- Emergency hospitalizations for adverse drug events in older Americans. (New England Journal of Medicine)
- Fibrinolysis for patients with intermediate-risk pulmonary embolism. (New England Journal of Medicine)
Their papers
- Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. (2010) — 781 citations
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. (2010) — 796 citations
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients (2010) — 2,386 citations
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. (2009) — 993 citations
- Apixaban or enoxaparin for thromboprophylaxis after knee replacement. (2009) — 726 citations
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. (2008) — 1,345 citations
- Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) (2008) — 889 citations
- Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial (2006) — 841 citations
- Prevention of venous thromboembolism. (2005) — 1,421 citations
- Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) — 2,925 citations
- Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. (2002) — 754 citations
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. (2001) — 650 citations
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. (2001) — 634 citations